This is a non-interventional study to review safety data on administration of desvenlafaxine succinate among Filipino patients with MDD and VMS per usual clinical practice within the first three years post commercial distribution.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs), or Discontinuation Due to Adverse Events (AEs)
Timeframe: Week 4 to Week 8
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Week 4.
Timeframe: Week 4
Change From Baseline in Systolic Blood Pressure (BP) and Diastolic BP at Week 8.
Timeframe: Week 8
Change From Baseline in Heart Rate at Week 4.
Timeframe: Week 4
Change From Baseline in Heart Rate at Week 8.
Timeframe: Week 8
Change From Baseline in Weight at Week 4.
Timeframe: Week 4
Change From Baseline in Weight at Week 8.
Timeframe: Week 8